Company intelligence / Profile preview

OrthoCellix

Malvern, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

NeoCart® is a first-in-class autologous cell therapy designed to restore knee cartilage; it has received FDA RMAT designation, prior clinical validation, and is expected to initiate a pivotal phase 3 trial in late 2025. A previous trial failed to demonstrate statistical superiority to chondroplasty, posing a key risk.

Therapeutic areas: Rheumatology
Modalities: Cell therapyAutologous cartilage implant
Industry: Biotech

Partnerships

No formally disclosed ongoing pharma/biotech partnerships; Ocugen supports manufacturing and infrastructureCarisma’s prior partnerships (e.g., Moderna) are discontinued as part of merger

Beyond the preview

Go deeper on OrthoCellix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrthoCellix.

Explore the full profile